# Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

> **NCT07348965** · NA · RECRUITING · sponsor: **Guangzhou University of Traditional Chinese Medicine** · enrollment: 42 (estimated)

## Conditions studied

- NSCLC (Advanced Non-small Cell Lung Cancer)
- Leptomeningeal Metastasis
- Furmonertinib
- EGFR Activating Mutation

## Interventions

- **DRUG:** Furmonertinib 320mg qod po
- **DRUG:** Furmonertinib 160mg qd po

## Key facts

- **NCT ID:** NCT07348965
- **Lead sponsor:** Guangzhou University of Traditional Chinese Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2028-09-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07348965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07348965, "Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07348965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*